What were the key takeaways from Certara's earnings call?

What is Certara's latest dividend and current dividend yield?

What were the key takeaways from Certara’s earnings call?

What is the market's earnings forecast for Certara next quarter?

What is Certara's gross profit margin?

What factors drove the changes in Certara's revenue and profit?

Did Certara beat or miss consensus estimates last quarter?

What guidance did Certara's management provide for the next earnings period?

- **Strategic Focus on AI**: CEO prioritizes AI integration into software and services, with new products like CertaraIQ and $10M+ AI-driven cost savings. 
- **2026 Growth Outlook**: Flat to 4% revenue growth, 30-32% EBITDA margin, and $0.44-$0.48 EPS, reflecting market cautiousness and operational reset. 
- **Services Resilience**: Services bookings surged 17% Q4/Q4, with MIDD and regulatory writing leading the way. 
- **FDA Regulatory Shift**: Increased use of computational modeling (e.g., QSP) by FDA creates growth opportunities for Certara's MIDD platforms. 
- **Share Buybacks**: $43M in 2025 share repurchases highlight management's confidence in long-term value.

**【CEO Summary Section】**
- Jon Resnick emphasized Certara's strategic focus on AI-driven innovation and customer-centric operations. He outlined three priorities: sharpening the product portfolio, enhancing customer engagement, and improving operational efficiency. 
- The company expects flat to low single-digit revenue growth in 2026, reflecting market conditions and operational improvements. 
- Resnick highlighted the potential for double-digit growth over time, driven by AI integration and MIDD (Model-Informed Drug Development) adoption. 
- The company is finalizing a strategic review of its regulatory writing business, with a focus on maximizing long-term value.

**【CFO Financial Commentary】**
- Q4 2025 revenue was $103.6 million, up 3% YoY. Full-year revenue was $418.8 million, growing 9% YoY. 
- Software revenue grew 10% Q4/Q4, driven by MIDD and Pinnacle 21. Services revenue was $57.3 million, down 1% YoY. 
- Adjusted EBITDA was $32.5 million (31% margin) in Q4, with full-year EBITDA of $134.5 million (32% margin). 
- 2026 guidance: flat to 4% revenue growth, 30-32% EBITDA margin, and $0.44-$0.48 EPS. 
- The company repurchased $43 million in shares in 2025 and plans to continue disciplined capital deployment.

**【Q&A Key Highlights】**
- **AI and Productivity**: Certara is embedding AI into core software (e.g., Phoenix) and launching new AI-native products like CertaraIQ. Internal AI adoption is expected to drive $10 million in cost savings in 2026. 
- **Software Bookings**: Q4 software bookings were $56.1 million (-6% YoY), impacted by market headwinds (e.g., pharma reorgs) and execution challenges. Management expects gradual improvement in 2026. 
- **Services Growth**: Q4 services bookings were $99.1 million (+17% YoY), driven by MIDD and regulatory writing. Full-year services revenue grew 3%. 
- **Regulatory Trends**: FDA adoption of computational modeling (e.g., QSP) is accelerating, with Certara's QSP technology enabling 50-100x higher first-in-human doses. 
- **Customer Engagement**: The company is investing in senior-level customer interactions and AI-driven sales automation to improve conversion rates.

Certara, Inc. (CERT) Q4 2025 Earnings Call Transcript

- **Revenue resilience**: Q3 revenue up 10% YoY to $104.6 million, with adjusted EBITDA margin of 34%.
- **Investment in growth**: R&D up 24% YoY, driving new product launches like Certara IQ (QSP modeling) and Phoenix Cloud.
- **Tiered customer dynamics**: Tier one services bookings down 9% YoY due to caution, while tier three biotech growth (+double digits) offsets weakness.
- **Margin expansion**: Gross profit boosted by software mix (65% ratable/subscriptions) and cost productivity, with EBITDA margin guidance raised to 32%.
- **2025 outlook**: Narrowed revenue range ($415-$420 million) reflects cautious tier one environment, but software growth and share buybacks support EPS guidance of $0.45-$0.47.

**【CEO Summary Section】**
- Q3 2025 revenue of $104.6 million, up 10% YoY, with adjusted EBITDA of $35.2 million (34% margin). R&D investment grew 24% YoY to 10% of revenue.
- Bookings of $96.6 million (+1% YoY) underperformed due to tier one customer caution, with 1% growth in software bookings and 9% decline in services.
- New product launches (Certara IQ, Phoenix Cloud) show early success, with QSP services growing ahead of the rest of the business.
- 2025 revenue guidance narrowed to $415-$420 million, with adjusted EBITDA margin raised to high end of guidance range (32%).

**【CFO Financial Commentary】**
- Software revenue: $43.8 million (+22% YoY), driven by Simcyp and Chemaxon ($5.6 million contribution). Services revenue: $60.8 million (+3% YoY), with QSP growth offsetting regulatory softness.
- Gross profit improved due to software mix (65% of software revenue from ratable/subscriptions) and cost productivity. Adjusted EPS: $0.14 vs. $0.13 YoY.
- Balance sheet: $172.7 million cash, $293.1 million term loan. Share buybacks: $41 million YTD.
- 2025 guidance: $415-$420 million revenue, 32% EBITDA margin, $0.45-$0.47 EPS.

**【Q&A Highlights】**
- **Tier 1 Customer Behavior**: Slowed decision-making in Q3 continued into Q4, with deals pushed to Q4 and 2026. Tier 3 biotech growth offset tier one weakness.
- **Gross Margin**: Productivity gains (e.g., services cost reductions) and software mix (Chemaxon licenses) drove margin expansion.
- **AI & Product Innovation**: Certara IQ (QSP modeling) and Phoenix Cloud (cloud migration) well-received, with QSP becoming a key growth driver.
- **Macro Impact**: Pharma onshoring and MFN pricing clarity may stabilize 2026 budgets, but near-term tier one caution persists.
- **Regulatory Services**: Inconsistent performance but cash generative; strategic review nearing conclusion.


Certara, Inc. (CERT) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: $104.6M (+12% YoY), bookings $112M (+13% YoY), driven by 22% YoY software growth and 15% services bookings.
- **Regulatory Milestone**: Simcyp becomes first AI-enabled PBPK platform qualified by EMA, reducing animal testing needs.
- **AI Platform Launch**: CertaraIQ QSP platform in early access, targeting Q4 2025 launch with 50% new QSP projects for mAbs.
- **Profitability**: Adjusted EBITDA $31.9M (+21% YoY), margin 31%, with $25M share buybacks completed.
- **Market Opportunity**: $10B+ addressable market for NAMs over 10 years, 70% of biosim customers using Simcyp for first-in-human dosing.

**【CEO Summary Section】**
- Q2 2025 revenue of $104.6 million (+12% YoY), bookings of $112 million (+13% YoY), with strong performance in software (+22% YoY) and services (+5% YoY). 
- Simcyp software achieved EMA qualification as the first AI-enabled PBPK modeling platform, positioning Certara as a regulatory leader.
- Launching CertaraIQ AI-enabled QSP platform in Q4 2025, with 50% of new QSP projects targeting monoclonal antibodies (mAbs) driven by FDA's NAM guidance.
- R&D investment in AI/MIDD platform continues, with $5.1M contribution from Chemaxon and 60% of software revenue from ratable/subscriptions.
- Full year guidance reaffirmed: $415-425M revenue, 8-10% growth, 30-32% EBITDA margin.

**【CFO Financial Commentary】**
- Q2 GAAP net loss of $2M (-83% YoY), adjusted EBITDA of $31.9M (+21% YoY), margin 31%.
- Software bookings $46.6M (+11% YoY), services bookings $65.4M (+15% YoY). 
- Software net retention rate 107.6%, with Tier 2/3 growth offsetting Tier 1 renewal timing delays.
- TTM bookings $470.8M (+15% YoY), trailing 12-month software bookings $181.9M (+25% YoY).
- $25M share buybacks completed Q2, $75M remaining under $100M program.

**【Q&A Highlights】**
- **NAM Market Opportunity**: CEO estimates $10B+ addressable market over 10 years, with 50% of new QSP projects targeting mAbs.
- **Customer Dynamics**: Tier 1 software renewals delayed but visible for H2, Tier 3 bookings up 15% YoY.
- **AI Platform Adoption**: CertaraIQ in early access, expected Q4 launch; no demand deferral observed.
- **Margins & Investments**: Q2 EBITDA margin 31%, R&D spend growing YoY; Q4 2025 as proxy for 2026 margin modeling.
- **Regulatory Environment**: FDA NAM guidance accelerating QSP adoption, 70% of biosim customers using Simcyp for first-in-human dosing.
- **Competitive Position**: Applied BioMath acquisition strengthens QSP leadership, 70% of QSP projects use Certara tools.

Certara, Inc. (CERT) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 revenue up 10% YoY to $106 million, driven by 23% software bookings growth and FDA tailwinds.
- **FDA Policy Win**: Non-Animal Navigator webinar drew 400+ attendees; first contracts expected beyond Q2 as pharma shifts to modeling.
- **Profitability Boost**: Adjusted EBITDA margin of 33% (vs. 29% YoY), with $34.8 million EBITDA reflecting strong cost control.
- **AI Differentiation**: AI-powered co-author product gaining traction, with customers exploring AI in biosimulation workflows.
- **Guidance Confidence**: FY 2025 revenue growth 8-10%, EBITDA margin 30-32%, signaling long-term biosimulation adoption.


**【CEO Summary Section】**
- Q1 2025 revenue reached $106 million, up 10% YoY, driven by software bookings growth of 23% and services bookings growth of 7%. Chemaxon contributed $5.9 million in revenue.
- FDA's phase-out of animal testing for monoclonal antibodies has generated significant interest, with over 400 attendees at a recent webinar on Certara's Non-Animal Navigator solution.
- Strategic focus on AI integration, biosimulation platform expansion, and early-stage drug development solutions to capitalize on regulatory tailwinds.

**【CFO Financial Commentary】**
- Q1 GAAP net income was $4.7 million, compared to a net loss of $4.7 million in Q1 2024. Adjusted EBITDA was $34.8 million, up 19% YoY, with a margin of 33%.
- Software revenue grew 18% YoY to $46.4 million, with 57% of software revenue from ratable and subscription models. Services revenue increased 4% to $59.6 million.
- Guidance for FY 2025: Total revenue $415-425 million (8-10% growth), adjusted EBITDA margin 30-32%, and adjusted EPS $0.42-0.46.

**【Q&A Key Highlights】**
- **FDA Policy Impact**: CEO noted over 800 webinar attendees across biotech, pharma, and government, with interest in replacing animal models for preclinical studies. First contracts for Non-Animal Navigator expected beyond Q2.
- **Market Penetration**: CFO highlighted 102% software net retention ratio, with 62% of software bookings from ratable models. Regulatory services bookings grew double digits YoY.
- **AI Investment**: CEO emphasized AI-driven products like co-author for regulatory reporting, with early adoption and customer interest in AI's role in biosimulation.
- **Tariff Concerns**: CFO reported no direct impact from pharma tariffs, but noted cautiousness in Tier 1 pharma decision-making affecting biosimulation services.
- **Cloud Adoption**: CEO noted Certara Cloud adoption through Phoenix renewals, with plans to enhance hosted Phoenix functionality to drive migration.


Certara (CERT)-5 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 9% YoY in 2024, Q4 bookings up 22% driven by software (38%) and services (12%).
- **Profitability**: Adjusted EBITDA margin 32%, net income $6.6 million vs. loss in Q4 2023.
- **Strategic Moves**: AI integration, Chemaxon acquisition, and CoAuthor success in regulatory writing.
- **Risks**: Cautious spending by Tier 1 and 3 customers may limit 2025 growth (8-10% guidance).

**【CEO Summary Section】**
- **2024 Revenue Growth**: $385.1 million, up 9% YoY, driven by strong software and services performance.
- **Q4 Bookings**: $144.5 million (+22% YoY), with software bookings up 38% and services 12%.
- **Customer Expansion**: 2,400+ customers, 431 with ACV >$100k (+11% YoY), and 67 with ACV >$1 million.
- **Strategic Investments**: AI integration, R&D expansion, and successful product launches (e.g., CoAuthor).
- **2025 Guidance**: 8-10% revenue growth, adjusted EBITDA 30-32%, and EPS $0.42-0.46.

**【CFO Financial Commentary】**
- **Q4 Revenue**: $100.4 million (+14% YoY), with software at $42.3 million (+26% YoY).
- **Chemaxon Contribution**: $6.6 million in Q4, ahead of expectations.
- **Adjusted EBITDA**: $33.5 million (+13% YoY), with net income of $6.6 million.
- **Full-Year Metrics**: Adjusted EBITDA of $122 million (32% margin), up from $108 million in 2023.

**【Q&A Key Highlights】**
- **End Market Dynamics**: Cautious spending by Tier 1 and 3 customers impacting net retention rate (106% Q4 vs. 108% FY24).
- **AI and Product Momentum**: CoAuthor gaining traction, Simcyp expanding via direct sales and projects.
- **Chemaxon Integration**: Expected to contribute $23-25 million in 2025, with margin impact offset by R&D investments.
- **Regulatory Services**: Q4 bookings growth, but Tier 2/3 softness limiting full-year recovery.

Actual	0.09	0.06	0.03	0.07	0.01	0.11	0.09	0.1	0.16	0.12	0.12	0.11	0.09	0.1	0.07	0.13	0.15	0.14	0.07	0.14	0.09
Forecast	0.0073	0.0458	0.0498	0.0575	0.0854	0.108	0.0962	0.1169	0.1299	0.1216	0.1253	0.1093	0.1095	0.103	0.1026	0.1078	0.123	0.1131	0.0995	0.1135	0.1118
Surprise	+1132.88%	+31.00%	-39.76%	+21.74%	-88.29%	+1.85%	-6.44%	-14.46%	+23.17%	-1.32%	-4.23%	+0.64%	-17.81%	-2.91%	-31.77%	+20.59%	+21.95%	+23.78%	-29.65%	+23.35%	-19.50%

CERT

CERT fundamentals

CERT Q4 2025 Earnings

Earnings Call

You can ask Aime

CERT

CERT fundamentals

CERT Q4 2025 Earnings

Earnings Call

CERT Earnings Call Summary for Q4/20258:30 AM on Feb 26, 2026

CERT Earnings Call Summary for Q3/20255:00 PM on Nov 6, 2025

CERT Earnings Call Summary for Q2/20255:00 PM on Aug 6, 2025

CERT Earnings Call Summary for Q1/20255:00 PM on May 5, 2025

CERT Earnings Call Summary for Q4/20245:00 PM on Feb 26, 2025

You can ask Aime